

The Landscape of Renal Replacement Therapy in Veterans Affairs Medical Center Intensive Care Units

Chandan Vangala (✉ vangala@bcm.edu)

Baylor College of Medicine

Maulin Shah

3989-Baylor College of Medicine

Natasha N. Dave

19994-Miami VA Healthcare System

Layth Al Attar

3989-Baylor College of Medicine

Sankar D. Navaneethan

3989-Baylor College of Medicine

Venkat Ramanathan

3989-Baylor College of Medicine

Susan Crowley

19985-VA Connecticut Health System

Wolfgang C. Winkelmayr

3989-Baylor College of Medicine

Research article

Keywords: Continuous Renal Replacement Therapy, Prolonged Intermittent Renal Replacement Therapy, CRRT, PIRRT, Veterans Affairs, Intensive Care Unit

Posted Date: September 15th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-67802/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Renal Failure on January 1st, 2021. See the published version at <https://doi.org/10.1080/0886022X.2021.1949347>.

Abstract

Background Outpatient dialysis is standardized with several evidence-based measures of adequacy and quality that providers aim to meet while providing treatment. By contrast, in the intensive care unit (ICU) there are different types of continuous and prolonged renal replacement therapies with numerous and varied strategies for addressing patient care and a dearth of nationally accepted quality parameters. In order to eventually understand what quality measures are appropriate for ICU-related renal replacement therapy (RRT), we first aimed to capture the variety and prevalence of basic strategies and equipment utilized in the ICUs of Veteran Affairs (VA) medical facilities with inpatient hemodialysis capabilities.

Methods Via email to the dialysis directors of all 87 VA facilities that provided inpatient hemodialysis during 2018, we requested participation in a survey regarding aspects of RRT in VA ICUs. Questions centered around mode of therapy, equipment, solutions, prescription authority, nursing, anticoagulation, antimicrobial dosing, and access.

Results Seventy-six centers completed the questionnaire, achieving a response rate of 87.4%. Fifty-five centers or 72.4%, reported using some form of prolonged or continuous renal replacement therapy (CRRT) in addition to intermittent hemodialysis. Of these 55 centers, 42 reported being specifically CRRT-capable. Over half of the respondents had the capabilities to perform prolonged intermittent renal replacement therapy (PIRRT). Twelve centers (21.8%) were equipped to use slow low efficient dialysis (SLED) alone. Therapy was overwhelmingly prescribed by nephrologists (94.4% of centers).

Conclusions Within the VA system, ICU-related RRT practice is quite varied. Variation in processes of care, prescription authority, RRT nursing care coordination, medication management, and safety practices present opportunities for developing cross cutting measures of quality of intensive care RRT that are agnostic of modality choice.

Summary

The Veterans Health Administration is the largest integrated healthcare system in the United States. Using the Veterans Affairs (VA) internal Dialysis Facility Directory, we sent surveys regarding renal replacement therapy practices in the intensive care unit to the dialysis directors of each VA facility that provided VA-staffed inpatient hemodialysis. With 76 responses out of total 87 facilities, we described prolonged and continuous renal replacement therapy with regards to basic aspects of treatment such as modality, equipment, solutions, anticoagulation, staffing, and access. This report helps educate on the heterogeneity of treatment and what principal common denominators could serve as potential quality measures to improve delivery of care.

Background

Prolonged intermittent renal replacement therapy (PIRRT) and continuous renal replacement therapy (CRRT) are frequently utilized in the intensive care unit in order to provide a more sustained duration of

solute and volume control in patient with tenuous hemodynamics. Outpatient renal replacement therapies, namely, intermittent hemodialysis (IHD) and peritoneal dialysis, have evidence-based measures that serve as guides to therapy[1]. While not hospitalized, patients are more likely to be in “steady state”, and nephrologists have goals for adequacy, phosphorus control, nutritional parameters, access, interdialytic weight gain, etc. However, in the intensive care unit, therapy remains varied by choice of modality, duration, and several ancillary factors relating to access, interruptions, and drug dosing.

The mortality of patients with acute kidney injury requiring IHD has improved in recent years[2]. However, patients with acute kidney injury requiring CRRT continue to face an estimated mortality rate of greater than 60%[3–6]. This discrepancy suggests more dire pathology and perhaps, a role for improving the quality of care provided with this therapy. The opportunity to delineate quality care may be best outlined within the largest integrated healthcare system in the United States, the Veterans Health Administration. Yet, a formidable obstacle in this goal is the facility-dependent variability surrounding prolonged and continuous renal replacement therapy.

Standardized goals or quality measures may be more easily identified with basic understanding of how therapy is administered across the country. We aimed to understand the variety of strategies and equipment utilized. Through an online survey, we conducted a descriptive analysis of RRT provided in VA-based ICUs.

Methods

We emailed the dialysis directors of all 87 Veterans Affairs medical centers with VA-staffed inpatient hemodialysis capabilities identified in VA's internal Dialysis Facility Directory and requested their voluntary participation in a questionnaire. We asked questions regarding general strategies and equipment for RRT in the ICU (**Supplemental Fig. 1**). Dialysis directors were encouraged to answer the questionnaire or suggest alternate staff that would be best equipped to answer questions pertaining to ICU-related care. We obtained the VA station name from which a response was obtained; no other identifying information was collected.

The survey was conducted using an online platform, SurveyMonkey® (www.surveymonkey.com), that utilized Secure Sockets Layer encryption. Our emailed request for participation included a URL, which directed responders to the online survey consisting of 21 questions (**Supplemental Figure F1**). The first question identified the VA institution where the responder was located. Fourteen of the questions were in multiple choice format while five questions were ‘yes/no’, and one question was an optional short answer allowing for a follow-up explanation of a previous answer. The questionnaire remained available to responders from December 1, 2018 to March 15, 2019. Responses were assessed as proportions. Only one response was allowed per participating center, but changes to answers were permitted at any time. Due to the acquisition of de-identified data, our request for IRB approval was waived (H-45304 memorandum) at the Baylor College of Medicine and Michael E. DeBakey VA, Houston, Texas, as it did not fall under the category of human subjects research.

Results

Of the 87 institutions that were requested to participate in the survey, 76 centers provided a response. Of those 76 centers, 21 (27.6%) centers reported IHD as the available modality of RRT and did not utilize prolonged or continuous therapies in the ICU. We found that 55 (72.4%) reported employing PIRRT or CRRT as RRT options. Of these, 13 (17.1%) centers utilized PIRRT without being CRRT-capable while 42 (55.3%) centers reported being CRRT-capable. Fewer centers with inpatient HD capabilities were located in the Rocky Mountain or West North Central region, but no obvious geographic trend towards particular types of therapies was evident (see Fig. 1). Thirty-four centers (44.7%) had the ability to provide inpatient peritoneal dialysis. A larger proportion of facilities with higher operational complexity were found to have CRRT capabilities (see Table 1).

Table 1
Renal Replacement Therapy by
Operational Complexity

Operational Complexity	
Standard	n = 1
IHD	1 (100.0)
Intermediate	n = 13
IHD only	6 (46.2)
CRRT	6 (46.2)
PIRRT	5 (38.5)
PIRRT alone	1 (7.7)
SLED alone	1 (7.7)
Complex	n = 62
IHD only	14 (22.6)
CRRT	36 (58.1)
PIRRT	23 (37.1)
PIRRT alone	12 (19.4)
SLED alone	11 (17.7)

Among those that provided CRRT, respondents reported almost equivalent CVVH (54.5%) and CVVHD (56.4%) capabilities; slightly fewer centers provided CVVHDF (47.3%). Slow low efficient dialysis was the predominant mode of PIRRT. Five centers reported utilizing prolonged veno-venous hemodialysis, also known as SHIFT therapy, and one center employed SHIFT as their primary mode of therapy in the ICU.

Only one center reported utilizing prolonged or accelerated veno-venous hemofiltration (AVVH), and while that center had the ability to perform CVVHD, AVVH was their primary form of RRT (see Table 2).

Table 2
Variety of Prolonged and Continuous Renal Replacement Therapy

Type of Prolonged or Continuous Renal Replacement Therapy (n = 55)	Respondents, n = 55 n (%)
CRRT (CVVH/CVVHD/CVVHDF)	42 (76.4)
CVVH	30 (54.5)
CVVHD	31 (56.4)
CVVHDF	26 (47.3)
PIRRT (SLED/SHIFT/AVVH)	28 (50.9)
SLED	23 (41.8)
SHIFT	5 (9.1)
AVVH	1 (1.8)
Exclusively PIRRT	13 (23.6)
Exclusively SLED	12 (21.8)
Exclusively SHIFT	1 (1.8)
Exclusively AVVH	0 (0.0)
<i>Note: CRRT – Continuous Renal Replacement Therapy; CVVH – Continuous Veno-Venous Hemofiltration; CVVHD – Continuous Veno-Venous Hemodialysis; CVVHDF – Continuous Veno-Venous Hemodiafiltration; PIRRT – Prolonged Intermittent Renal Replacement Therapy; SLED – Slow Low Efficient Dialysis; AVVH - Accelerated Veno-Venous Hemofiltration;</i>	

Twenty-seven percent of centers with capabilities for prolonged or continuous therapy would access a fistula or graft for therapy. All centers reported the requirement of having a HD nurse with constant visualization fo the access as a special safety precaution for this practice, which is consistent with the VA National Center for Patient Safety’s recommended practice[7]. More than half of the facilities endorsed using triple-lumen, non-tunneled, temporary catheters equipped with an additional port for infusions. The catheter lengths utilized were highly varied, but the majority reported having catheters of lengths 15–16 centimeters and 19–20 centimeters (see Table 3).

Table 3
Access-Related Responses

Access	n (%)
Anticoagulant Locking (responses = 76/76; 100%)	
Temporary catheter	55 (72.4)
Tunneled dialysis catheter	52 (68.4)
Locking Content (responses = 76/76; 100%)	
Citrate	9 (11.8)
Heparin	47 (61.8)
Saline	19 (25.0)
Alteplase	1 (1.3)
Catheter Length (responses = 68/76; 89.5%)	
12-13.5 cm	21 (30.9)
15–16 cm	42 (61.8)
19–20 cm	53 (77.9)
23–25 cm	31 (45.6)
> 25 cm	7 (10.3)
Temporary Triple-Lumen Dialysis Catheter Use during Renal Replacement Therapy (responses = 76/76; 100%)	41 (54.0)
Arteriovenous Fistula/Graft use during CRRT/PIRRT (responses = 55/55; 100%)	15 (27.3)

Prescribers of therapy were largely nephrologists, consistent with VHA policy[8], with only one center relying on intensivists for RRT. All centers had ICU nurses directly managing CRRT with 23.1% of centers having HD nurses facilitate set-up. By contrast, with PIRRT, the majority of therapy was managed by HD nurses, usually for slow low efficient dialysis (SLED). Nearly 63% of centers had either an ICU or HD nurse stationed one-to-one with patients requiring prolonged or continuous therapies (see Table 4).

Table 4
Staffing-Related Responses

Providers of Prolonged/Continuous Therapy (responses = 55/55;) n (%)	
Intensivist	1 (1.8)
Nephrologist	52 (94.5)
Combined Intensivist/Nephrologist	2 (3.6)
Direct Manager of CRRT (responses = 41/42; 95.2%)	
ICU nurse	31 (77.5)
HD Nurse	1 (2.4)
HD nurse set-up, ICU manage	9 (23.1)
Direct Manager of PIRRT (responses = 28/28; 100.0%)	
ICU nurse	3 (10.7)
HD Nurse	17 (60.7)
HD nurse set-up, ICU manage	8 (28.6)
1:1 staffing (responses = 54/55; 98.2%)	34 (63.0)
1:1 for PIRRT only (responses = 8/13; 61.5%)	4 (50.0)
1:1 for CRRT only (responses = 26/27; 96.3%)	17(65.4)

Compared to regional citrate anticoagulation, heparin anticoagulation appeared to be utilized with more frequency during CRRT (see Fig. 2). Among facilities that provided CRRT, most (68.3%) reported never using regional citrate anticoagulation. During SLED, 70% of respondents reported never using regional citrate anticoagulation and 30% reported infrequently (< 20% of the time) using regional citrate anticoagulation. As with CRRT, heparin anticoagulation also remained slightly more prevalent during SLED (see **Supplemental Table S2**). Of the 40 centers that practiced CRRT, nearly two thirds used one brand's device and the other third used an alternate brand's device (see **Supplemental Table S1**). One brand's solutions appeared to be the most commonly adopted with 70.7% of centers endorsing use. One institution generated their own tailor-made replacement fluid. Of the CRRT-capable centers, 46.2% carried therapy fluid with both 2 mEq/L and 4 mEq/L of potassium, while 25.6% carried therapy fluid of all three varieties of common potassium concentrations (see **Supplemental Table S1**). Antibiotic dosing was frequently a multidisciplinary practice, with 81.8% of centers relying on the input of pharmacists, and 20.8% of centers solely relying on pharmacist input. The addition of nephrology input to pharmacy was present in 62.2% of centers. A multidisciplinary effort among the primary intensivist, nephrologist, and pharmacist was reported in 35.8% of centers (see **Supplemental Table S3**).

Discussion

Among VA medical centers with capabilities for inpatient HD, the use of prolonged or continuous renal replacement therapy in the ICU is not uncommon. Of the 55 centers that offer PIRRT and/or CRRT, more than three-quarters reported some form of continuous therapy. While not directly assessed in this study, practitioner preference, facility-level constraints related to staffing, cost, and utility, available surgical services, and coordination with ICU staff are likely some of the determinants of therapy availability. Continuous therapies offer a practical advantage of gradual solute and volume control, particularly useful in post-operative patients with acute kidney injury.

The above conveniences of CRRT comes at the cost of additional staffing and equipment, both of which require training, vigilant monitoring, and management[9]. Accordingly, facilities with higher level of operative complexity, and therefore more complex surgical services offered, were more likely to be equipped with CRRT. Flexible staffing presents a critical constraint that often determines therapy availability. CRRT is mostly set-up and managed by ICU nurses while PIRRT, particularly SLED, appears to have more involvement of HD nurses. While not assessed in this study, this division and staffing availability from either department could possibly influence the modes of therapy made available within a center.

One-to-one nurse staffing was employed among the majority of VA facilities that offered prolonged or continuous therapy. This staffing model supports VA National Center for Patient Safety's recommendation for continuous visual monitoring of dialysis vascular access, especially in patients at highest risk for bleeding from access dislodgement, such as those receiving RRT in the ICU setting[10]. More thorough investigations of staffing models are needed to better understand responsiveness and ability to troubleshooting circuit failure and how well prescribed therapies are delivered. As critical care complexity grows with extracorporeal membrane oxygenation and ventricular assist devices, nursing teams dedicated to RRT initiation and troubleshooting may become valuable[11].

More than half of VA facilities surveyed are PIRRT-capable. Comparative advantages relative to CRRT include less depletion of water-soluble minerals that are easily filtered[12] and reduced losses of amino acids and protein[13], potentially enabling achievement of recommended net protein balance[14, 15]. While PIRRT is understudied in this regard and dosing is highly variable, the extended periods without clearance could potentially result in fewer nutritional losses, which may be key to some patients' recoveries. Additionally, the cost of staffing with additional one-to-one nursing time, the increased potential for clotting and blood loss, and reduced patient mobility all present additional setbacks to CRRT use. PIRRT fills a need of transitional therapy that limits many of the detrimental aspects of CRRT and the cost of additional staffing. However, as discussed later, drug dosing is not well understood and may limit providers' comfort with use in patients with critical needs for accurate dosing of medications within therapeutic indices. Importantly, while no modality has demonstrated superiority in large generalizable trials, with further study there potentially exists an opportunity to outline select patients for whom PIRRT offers less complications.

Both the U.S. General Service Administration's centralized procurement system and the choice of RRT may influence purchasing decisions among VA centers. Survey findings indicate that one brand's therapy fluids are most commonly used, likely because its replacement fluid and dialysates are compatible with all forms of continuous therapy (CVVH, CVVHD, CVVHDF) and with both CRRT devices used within the VA system (see **Supplemental Table S1**). The majority of VA institutions with CRRT capabilities utilize a single vendor's device and therapy fluid. Therapy fluids content differs minimally across the three major manufacturers reported to be used by VA facilities, and therefore, is unlikely to yield distinct clinical outcomes per solution type.

Regarding catheter care, and specifically locking solutions, limited quality evidence exists to support the use of any particular packing solution over another, and heparin use has become quite common. Our study similarly reflects that heparin is the most commonly used locking agent among VA centers. Whether it presents advantages over saline remains uncertain, and yet it is the standard by which alternative anticoagulants are assessed[16]. In a Cochrane review of 27 studies conducted by Wang and colleagues, tissue plasminogen activator was the only agent that reduced catheter malfunction over standard of care[16]. However, the bleeding concern associated with injection or leak is a considerable deterrent, especially in surgical intensive care units. Notably, only one VA facility reported using tissue plasminogen activator for locking catheters. While not uniformly consistent, some studies suggest a reduced incidence of catheter-related bacteremia with citrate use[16]. Importantly, most of these studies were not conducted in AKI requiring RRT, and the largest study to date to compare heparin vs. citrate use in patients with AKI requiring RRT via non-tunneled dialysis catheter noted no difference in event-free survival of catheter, thrombosis, infection, or adverse events[17]. Thus, currently, no uniform recommendation regarding catheter-locking can be suggested.

Slightly more than half of respondents reported using triple-lumen temporary catheters. The impact of this additional port on catheter related infection is unknown, but just as muddy is the potential for increased clearance of vital medicines, particularly antibiotics, infused through these ports. Interestingly, almost a third of respondents carried catheters of around 12-13.5 cm, which may have limited utility in a predominantly male VA population[18][19]. However, we did not assess how frequently these smaller catheters were deployed, and therefore, we cannot comment on appropriateness of use.

Primary strategies for reducing blood loss from filter clotting include pre-emptive filter changes or anticoagulation. Anticoagulation has the added benefit of limiting time away from therapy, as changing out filters requires substantial disassembly and set-up. It also does not incur the costs of additional filters, but whether this is more cost-effective is still uncertain given the additional medications and monitoring required with anticoagulation. Compared to heparin, regional citrate anticoagulation in select patients has demonstrated increases in filter life as well as decreases in complication rates, blood loss, and therapy interruptions[20–23]. The Kidney Disease: Improving Global Outcomes 2012 guideline on acute kidney injury maintains a 2B recommendation for anticoagulation use in patients requiring CRRT, but only in those who do not have an “increased bleeding risk or impaired coagulation” or liver dysfunction or shock, and only in centers with an established protocol[24]. The use of regional citrate

anticoagulation is limited to 0–20% of patient treatments whereas heparin remains the most common form of anticoagulation worldwide in CRRT[24]. Heparin use is likewise favored among VA centers with CRRT capabilities, with regional citrate anticoagulation practiced by approximately 1/3rd of facilities (See Fig. 2). The complexity of coordinating across several disciplines – physicians, pharmacy, nursing, respiratory therapy, laboratory – to manage two infusions with frequent monitoring may be the main aversion to use. Despite studies endorsing safety, the potential for error-induced hypocalcemia and citrate accumulation or net citrate overload may present significant concerns for centers with limited prior experience. More evidence in the form of a large randomized, multi-center trial is imminent[25] and could potentially further illuminate the benefits and harms of RCA in CRRT.

Antimicrobial dosing for patients on RRT in the ICU is immensely challenging. Variability among intrinsic patient characteristics, clinical condition, and preferred prescriptions by different practitioners renders valid clearance studies in CRRT rather difficult; however, theoretical estimates of clearance can be made from the total delivered therapy fluid dose and the protein-binding of that drug[26]. Unfortunately, real-world evidence for dosing is limited to studies using more antiquated methods of CRRT. More often than not, patients requiring CRRT are administered inadequate doses of antimicrobials[27–29]; similar concerns exist with SLED[30]. Limited guidance exists for PIRRT as the therapy results in both periods of substantial clearance and negligible clearance. The only available guidance for dosing antimicrobials on AVVH and SHIFT are derived from in silico studies[31–33], limiting many providers' comfort with use in patients with infections or substantial concerns for infections. Even in SLED, a particular form of PIRRT that has historically been in use longer than other modes (AVVH and SHIFT), pharmacists do not agree on the dosing of commonly used antimicrobials[34]. Thus, sole reliance on pharmacy input may be insufficient for accurate dosing. The dynamic nature of patient courses and complementary therapy chosen necessitates frequent interdisciplinary communication regarding medication dosing. The majority of VA centers, as reported by nephrologists or their designees, endorse input from both pharmacy and nephrology regarding antimicrobial dosing. Mechanisms that ensure that providers who order antimicrobials are frequently (at least daily) educated of the renal replacement therapy plan is paramount to ensuring our best estimations of drug doses.

Limitations of this study include reliance on providers' recall. We likely garnered reliable responses regarding modes of therapy, machine type, solution type, and other variables related to therapy that are commonly encountered on a daily basis. However, the actual use of more detailed aspects of care such as initiation and stopping points for RRT, nutritional support, diuretic use, deployment of catheter of specific lengths (as compared to stock availability) are not captured. Additionally, questions regarding frequency of anticoagulation and provider input on antimicrobial dosing are more subjective impressions of the respondents. Regardless, these questions still served the purpose of underscoring the preferential equipment and supply use, anticoagulation strategies, nurse staffing models, and multidisciplinary input into antimicrobial dosing for RRT within the VA. Unfortunately, comparable data outside the VA system was not available. Additionally, in order to keep the questionnaire brief enough to maximize the response rate, we were limited in how comprehensive our study could be. Other than noting the prevalence of peritoneal dialysis, we did not assess any characteristics or equipment related to peritoneal

dialysis therapy. We did not request responses regarding French size of catheters, or whether catheters were straight, pre-curved, or with curved extensions. We also did not capture adherence to other VA required RRT practice standards (e.g. mandatory time-out pre-RRT, dedicated water hook ups, adherence to current ISO water standards, completion of life sustaining treatment directive). We did not capture whether pharmacy assisted with therapy fluid preparation. Lastly, we did not collect responses from 11 centers with inpatient HD capabilities. Our use of a simpler online tool with less flexibility allowed for non-responses among CRRT-capable surveyees, an option intended to be reserved for respondents that were exclusively HD-capable. Nonetheless, with a response rate of 87.4% and only a few inappropriate non-responses among seven questions, we believe that we received a sizable sample that serves to adequately describe the variety of strategies and equipment surrounding RRTs in Veteran Affairs ICUs.

Within the largest integrated healthcare system in the United States, we described diverse approaches to RRT. While we documented significant variation in modality and supply use, this study uncovers significant opportunities to explore measures of quality care which are agnostic of RRT modality. With the exception of catheter size and adequate length per location, limited evidence exists to distinguish particular equipment or solutions. The broader, primary objective of continuous and prolonged renal replacement therapy is to deliver precise and consistent treatment that minimizes harm to patients. Aligned with this aim, practitioners should ideally deliver adequate and steady solute and volume control, while concomitantly limiting blood loss, nutritional deficiencies, and errors in drug dosing. Given the variety of treatment, broadly applicable quality measures should be an initial area of focus for improving CRRT and PIRRT. Previous suggestions include ratios of prescribed to delivered therapy, time devoted to malfunction-related suspension of therapy, assessments of target solute clearance in effluent, filter clots, and blood loss[35]. As highlighted in this study, facility and organizational level variation exists in a number of other processes of care related to RRT in the ICU. By virtue of their RRT modality independence, parameters such as care coordination with antimicrobial dosing, nursing models for RRT delivery, RRT prescription authority, vascular access insertion and management, institutional safety standards, may also be well suited for assessment of cross cutting quality measures in the future. The landscape of RRT in the ICU has never been described at this level, and this report serves to educate further on options for addressing ICU-related care.

Abbreviations

AVVH: Accelerated Venovenous Hemofiltration

CVVH: Continuous Venovenous Hemofiltration

CVVHD: Continuous Venovenous Hemodialysis

CVVHDF: Continuous Venovenous Hemodiafiltration

CRRT: Continuous Renal Replacement Therapy

ICU: Intensive Care Unit

IHD: Intermittent Hemodialysis

PIRRT: Prolonged Intermittent Renal Replacement Therapy

RRT: Renal Replacement Therapy

SLED: Slow Low Efficiency Dialysis

VA: Veterans Affairs

Declarations

Ethics Approval and Consent to Participate:

This study is in accordance with Helsinki Declaration. Our request for IRB approval was waived (H-45304 memorandum) at the Baylor College of Medicine and Michael E. DeBakey VA, Houston, Texas. The information in this activity was de-identified so no authorization or waiver of authorization by patients for the release of individually identifiable protected health information was required. The activity did not fall under the regulations for IRB review of human subjects research found at 45 CFR 46.102(f) as the information is not individually identifiable. Thus, the study was granted a waiver of informed consent.

The interpretation and reporting of this data are the responsibility of the authors and do not reflect the official policy or interpretation of the US Government or the Department of Veterans Affairs.

Consent to Publish:

Not Applicable.

Availability of Data and Materials:

All relevant data are included within paper.

Funding:

The authors received no specific funding for this study.

Competing Interests:

Financial Disclosures: WCW reports having served as an advisor or consultant, unrelated to the topic of this manuscript, to Akebia, Amgen, Astra-Zeneca, Bayer, Daichii-Sankyo, Janssen, Relypsa, and Vifor-Fresenius Medical Care Renal Pharma. Outside the submitted work, SDN has served on an independent event adjudication committee for clinical trials sponsored by Bayer and Boehringer Ingelheim, served as a consultant to Tricida and Reata pharmaceuticals and received investigator-initiated research support

from Keryx Biopharmaceuticals. NND reports having served as a consultant, unrelated to the topic of this manuscript, for Tricida pharmaceuticals. MS receives research support from Medspace/Lenard-Meron Biosciences. All other authors have no financial disclosures to report.

Authors' Contributions:

C.V. participated in data acquisition, study design, performed statistical analysis, drafted manuscript, performed bibliographic search, and interpreted results of analysis. S.C. was involved in data acquisition, interpretation of results, and manuscript revision. M.S., N.D, L.A.A., V.R., S.D.N., and W.C.W. were involved in interpretation of results and made important contributions to revising the manuscript for important intellectual content. Each author contributed important intellectual content to manuscript drafting and revision. All authors approved the final manuscript.

Acknowledgements:

The work was supported using facilities and resources of the Veterans Health Administration Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety through grant CIN13-413.

References

1. **KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.** *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2015, **66**(5):884-930.
2. Brown JR, Rezaee ME, Hisey WM, Cox KC, Matheny ME, Sarnak MJ: **Reduced Mortality Associated with Acute Kidney Injury Requiring Dialysis in the United States.** *American journal of nephrology* 2016, **43**(4):261-270.
3. Hussain S, Piering W, Mohyuddin T, Saleh M, Zhu YR, Hannan M, Cohen E: **Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study.** *Hemodialysis international International Symposium on Home Hemodialysis* 2009, **13**(2):205-214.
4. Stads S, Fortrie G, van Bommel J, Zietse R, Betjes MG: **Impaired kidney function at hospital discharge and long-term renal and overall survival in patients who received CRRT.** *Clinical journal of the American Society of Nephrology : CJASN* 2013, **8**(8):1284-1291.
5. Prasad B, Urbanski M, Ferguson TW, Karreman E, Tangri N: **Early mortality on continuous renal replacement therapy (CRRT): the prairie CRRT study.** *Canadian journal of kidney health and disease* 2016, **3**:36.
6. Kao CC, Yang JY, Chen L, Chao CT, Peng YS, Chiang CK, Huang JW, Hung KY: **Factors associated with poor outcomes of continuous renal replacement therapy.** *PloS one* 2017, **12**(5):e0177759.
7. **Bleeding episodes during dialysis.** In. Edited by Safety VNCfP: VA Central Office; 2008.
8. **VHA Handbook 1042.01 Criteria and Standards for Dialysis in VA.** In. Department of Veterans Affairs Veterans Health Administration; 2016.

9. Graham P, Lischer E: **Nursing issues in renal replacement therapy: organization, manpower assessment, competency evaluation and quality improvement processes.** *Seminars in dialysis* 2011, **24**(2):183-187.
10. **Redsense Dialysis Alarm for Patients Undergoing Needle Access Procedures.** In. Edited by Safety VNCfP: VA Central Office; 2010.
11. Baldwin I: **Is there a need for a nurse emergency team for continuous renal replacement therapy?** *Contributions to nephrology* 2007, **156**:191-196.
12. Honore PM, De Waele E, Jacobs R, Mattens S, Rose T, Joannes-Boyau O, De Regt J, Verfaillie L, Van Gorp V, Boer W *et al.* **Nutritional and metabolic alterations during continuous renal replacement therapy.** *Blood purification* 2013, **35**(4):279-284.
13. Wooley JA, Btaiche IF, Good KL: **Metabolic and nutritional aspects of acute renal failure in critically ill patients requiring continuous renal replacement therapy.** *Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition* 2005, **20**(2):176-191.
14. Bellomo R, Tan HK, Bhonagiri S, Gopal I, Seacombe J, Daskalakis M, Boyce N: **High protein intake during continuous hemodiafiltration: impact on amino acids and nitrogen balance.** *The International journal of artificial organs* 2002, **25**(4):261-268.
15. Scheinkestel CD, Adams F, Mahony L, Bailey M, Davies AR, Nyulasi I, Tuxen DV: **Impact of increasing parenteral protein loads on amino acid levels and balance in critically ill anuric patients on continuous renal replacement therapy.** *Nutrition (Burbank, Los Angeles County, Calif)* 2003, **19**(9):733-740.
16. Wang Y, Ivany JN, Perkovic V, Gallagher MP, Woodward M, Jardine MJ: **Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.** *The Cochrane database of systematic reviews* 2016, **4**:Cd009631.
17. Quenot JP, Helms J, Bourredjem A, Dargent A, Meziani F, Badie J, Blasco G, Piton G, Capellier G, Mezher C *et al.* **Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial.** *Annals of intensive care* 2019, **9**(1):75.
18. Czepizak CA, O'Callaghan JM, Venus B: **Evaluation of formulas for optimal positioning of central venous catheters.** *Chest* 1995, **107**(6):1662-1664.
19. Fryar CD, Gu Q, Ogden CL: **Anthropometric reference data for children and adults: United States, 2007-2010.** *Vital and health statistics Series 11, Data from the National Health Survey* 2012(252):1-48.
20. Zhang Z, Hongying N: **Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy.** *Intensive care medicine* 2012, **38**(1):20-28.
21. Gao J, Wang F, Wang Y, Jin D, Tang L, Pan K: **A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.** *Scientific reports* 2019, **9**(1):6607.

22. Ricci D, Panicali L, Facchini MG, Mancini E: **Citrate Anticoagulation during Continuous Renal Replacement Therapy.** *Contributions to nephrology* 2017, **190**:19-30.
23. Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW: **Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.** *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2012, **59**(6):810-818.
24. Group KDIGOKAKIW: **KDIGO Clinical Practical Guideline for Acute Kidney Injury.** *Kidney Int, Suppl* 2012, **2**:1-138.
25. Meersch M, Küllmar M, Wempe C, Kindgen-Milles D, Kluge S, Slowinski T, Marx G, Gerss J, Zarbock A: **Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial.** *BMJ open* 2019, **9**(1):e024411.
26. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL: **Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2005, **41**(8):1159-1166.
27. Wilson FP, Berns JS: **Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD).** *Clinical nephrology* 2012, **77**(4):329-331.
28. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F: **Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.** *Critical care (London, England)* 2011, **15**(3):R137.
29. Shaw AR, Chaijamorn W, Mueller BA: **We Underdose Antibiotics in Patients on CRRT.** *Seminars in dialysis* 2016, **29**(4):278-280.
30. Keough LA, Krauss A, Hudson JQ: **Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.** *International journal of clinical pharmacy* 2018, **40**(5):1250-1256.
31. Lewis SJ, Kays MB, Mueller BA: **Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.** *Journal of clinical pharmacology* 2016, **56**(10):1277-1287.
32. Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA: **A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.** *Journal of clinical pharmacology* 2018, **58**(10):1254-1265.
33. Gharibian KN, Mueller BA: **Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach.** *Clinical nephrology* 2016, **86**(7):43-50.
34. Mei JP, Ali-Moghaddam A, Mueller BA: **Survey of pharmacists' antibiotic dosing recommendations for sustained low-efficiency dialysis.** *International journal of clinical pharmacy* 2016, **38**(1):127-134.
35. Bagshaw SM, Chakravarthi MR, Ricci Z, Tolwani A, Neri M, De Rosa S, Kellum JA, Ronco C: **Precision Continuous Renal Replacement Therapy and Solute Control.** *Blood purification* 2016, **42**(3):238-247.

Figures




Figure 1

Map of Types of Renal Replacement Therapy Used in Veterans Affairs Intensive Care Units with Intermittent Hemodialysis Capabilities. Accessed and edited from Wikimedia Commons with permission from author.




Figure 2

Anticoagulation on Continuous Renal Replacement Therapy

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementalMaterial.docx](#)
- [SupplementalMaterial8292020.docx](#)